Otsuka Pharmaceutical Co. Ltd. and Lundbeck recently announced the FDA approved extended-release injectable suspension Abilify Maintena for maintenance monotherapy of bipolar I disorder in adults.

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder, with or without ...

ABILIFY is also indicated for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder, and for maintaining efficacy in adults with Bipolar I Disorder with a recent manic or ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

Erin Crown, PA-C, CAQ-Psychiatry is a paid consultant of ®2024 Otsuka America Pharmaceutical, Inc. and Lundbeck, manufacturers of ABILIFY ASIMTUFII ® (aripiprazole) and ABILIFY MAINTENA ® ...

The UK’s National Institute for Health and Care Excellence (NICE) has backed the use of Otsuka’s Abilify in teenagers with bipolar disorder. The cost-effectiveness watchdog for the NHS in England and ...

Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...

“Smart pills” that can track whether or when you’ve taken your medication might be helpful for some people. Unfortunately, the first smart pill approved by the Food and Drug Administration, Abilify ...

Pdoc decided to transition me from AdderallXR to Abilify last Wednesday. Gave me a taper off schedule that had me off AdderallXR by Sunday and starting Abilify on Monday.<BR><BR>Saturday morning I was ...